Low Dose Immunotherapy (LDI)

Whereas an allergy occurs when the immune system no longer tolerates the external environment, an Auto-immune disease occurs when the immune system no longer tolerates the internal environment of the body.

In turn, whereas Low Dose Allergen (LDA) Therapy, makes use of an enzyme (beta-glucuronidase) that promotes tolerance (a chemotactic signal to certain regulatory lymphocytes) to administered antigens in order to restore immune tolerance to the environment outside the body. Low Dose Immunotherapy (LDI) does the same to administered antigens in order to restore immune tolerance to the environment inside the body.

What is it?

LDI is an extremely low dose immunotherapy that uses broad-based mixtures of bacterial, viral and environmental antigens made immunologically active by the enzyme glucuronidase. It is an extension from Low Dose Allergy (LDA) Therapy, and its treatment, action, and administration are similar; for more information please see our LDA therapy page.

What it does

Following the administration of the LDI, there is an increase in T regulator cells (Treg). The Treg cells address inappropriate cellular responses to substances promoted by CD4 (helper), CD8 (killer) and B Cells (this is where the immune system has been trying to protect you from things like food, environmental inhalants or even your own tissues). Simply put, this “shuts off” the allergic or adverse response.

Beta glucuronidase is recognized as a natural biological response modifier and is likely to be a significant physiological up regulator of the lymphocytic immune system.

All present evidence is that LDI restores the natural active cellular immune tolerance to specific environmental allergens, along with specific bacterial and viral antigens, which have become deregulated in autoimmune disease.

Auto Immune Diseases that have responded to treatment:

Inflammatory Bowel Disorders (Crohn’s & Ulcerative Colitis), Inflammatory Arthritis, Reactive Arthritis, Ankylosing spondylitis, ITP, Interstitial cystitis, Auto-immune thyroiditis (Hashimotos), SLE (lupus), Psoriasis, Lyme Disease, Fibromyalgia & Chronic Fatigue Syndrome.

The Safety of Low Dose Allergy Immunotherapy

LDI uses a natural pathway of immune modulation at a strength less than that which occurs in nature. An initial study of over 10,000 patients done in the US from 1993-2001 found no significant adverse reactions to LDI. Many double-blinded studies have proven the effectiveness and safety of the LDI treatment.

When to take LDI Injections

The injections are given at 4-8 week intervals (allowing the T cells to mature) for 6 – 18 sessions depending on the complexity/duration of your symptoms. In other words, the injections are given every 2 months at first, and after the first year become less frequent. The goal is to have the injection as little as possible.